Carfilzomib and Belatacept for Desensitization (ADAPT)
Highly Sensitized Prospective Kidney Transplant Recipients

About this trial
This is an interventional treatment trial for Highly Sensitized Prospective Kidney Transplant Recipients focused on measuring calculated panel reactive antibodies (cPRA), desensitization therapy, human leukocyte antigen (HLA) desensitization
Eligibility Criteria
Inclusion Criteria:
Individuals who meet all of the following criteria are eligible for enrollment as study subjects-
- Subject must be able to understand and provide informed consent
- End stage renal disease (ESRD) on dialysis
United Network for Organ Sharing (UNOS) listed for a kidney transplant with any one of the following:
- Current calculated panel reactive antibodies (cPRA) ≥ 99.9 percent awaiting deceased donor transplant
- Current cPRA >98 percent (with >5 years of waiting time) awaiting deceased donor transplant
- Current cPRA >98 percent with Human Leukocyte Antigen (HLA)-incompatible approved living donor and has not received a transplant after 1 year in a kidney paired exchange program
- Evidence of established immunity to Epstein-Barr virus (EBV) as demonstrated by serologic testing
Negative result of most recent tuberculosis (TB) testing or appropriately completed latent tuberculosis infection (LTBI) therapy.
- Testing should be conducted using either a purified protein derivative (PPD) or interferon-gamma release assay (i.e. QuantiFERON-TB, T-SPOT.TB).
- Negative results from tests performed within 12 months prior to study entry are acceptable in the absence of any intervening exposure to TB.
Subjects with a positive test result must have completed appropriate therapy for LTBI.
- Note: LTBI treatment regimens should be among those endorsed by the Centers for Disease Control and Prevention (CDC), url: https://www.cdc.gov/tb/topic/treatment/ltbi.htm
- Negative Food and Drug Administration (FDA)-approved test for human immunodeficiency virus (HIV) diagnosis (at screening or as documented in medical record, up to 12 months prior to screening)
Negative Hepatitis C antibody test at screening or as documented in medical record, up to 12 months prior to screening.
--If there is a history of treated hepatitis C or there is a suspected false positive hepatitis C virus (HCV) antibody test, then documentation of two consecutive negative HCV quantitative ribonucleic acid (RNA) polymerase chain reaction (PCR) tests separated by at least 6 months is required
- Negative result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase- polymerase chain reaction (RT-PCR)
Subjects must have an echocardiogram within the previous 1 year without any of the following findings:
- severe left ventricular hypertrophy (LVH)
- greater than mild LVH accompanied by diastolic dysfunction
- left ventricular ejection fraction <40 percent
- pulmonary hypertension defined as right ventricular systolic pressure >35 mm Hg or tricuspid regurgitant velocity >2.8 m/s
- Female subjects of reproductive potential must have a negative pregnancy test upon study entry
- All subjects of reproductive potential must agree to use contraception for the duration of the study
Subjects must have current vaccinations or documented immunity to:
- varicella (chickenpox)
- measles
- hepatitis B
- pneumococcus
- influenza, and
varicella zoster (if ≥ 50 years old).
- Note: If subjects require administration of either live or killed vaccines to meet eligibility requirements, they must wait at least 2 weeks between vaccination and the baseline visit (i.e., at least 4 weeks before initiation of therapy)
Living Donor Inclusion Criteria:
Living donors must meet all of the following criteria to be eligible-
- Able to understand and provide informed consent for research
- Meets United Network for Organ Sharing (UNOS) requirements for kidney organ donation
Exclusion Criteria:
Individuals who meet any of these criteria are not eligible for enrollment as study subjects-
- Inability or unwillingness of a subject to give written informed consent or comply with study protocol
- Known active current or history of invasive fungal infection, non-tuberculous mycobacterial infection
- Hepatitis B surface antigen or core antibody positive
- Serious uncontrolled concomitant major organ disease, excluding kidney failure
- Chronic respiratory failure
- Uncontrolled systemic hypertension
- Previous non-kidney solid organ transplant or bone marrow transplant
- Any infection requiring hospitalization and intravenous (IV) therapy within 4 weeks of screening or oral therapy within 2 weeks of screening
- History of positive result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase reverse transcriptase-polymerase chain reaction (RT-PCR)
- Primary or secondary immunodeficiency
- History of thromboembolism (except thrombosis of dialysis vascular access site)
- Subjects with myocardial infarction within 12 months of screening or cardiac dysrhythmias uncontrolled by medications
- History of plasma cell dyscrasia
- Known bleeding diathesis or coagulation abnormality
- History of active tuberculosis (TB) (even if treated)
- Malignancy within the last 5 years except treated basal and squamous cell cancer of the skin or treated cervical cancer in situ
- Women who are currently pregnant or nursing
- Alcohol, drug, or chemical abuse within 1 year
- Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational drug, whichever is longer) of screening
- Current treatment with other biological drug
- Current treatment with any medication which increases the risk of thromboembolic events including oral contraceptives
- Currently smoking tobacco
- Neutropenia (absolute neutrophil count <1000/microliter) or thrombocytopenia (platelet count <100,000/microliter) within 4 weeks prior to screening
- Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times upper limit of normal (ULN) or total bilirubin ≥ 2 times ULN
Past or current medical problems or findings from physical examination or laboratory testing not listed above, which, in the opinion of the investigator, may:
- pose additional risks from participation in the study
- interfere with the subject's ability to comply with study requirements, or
- impact the quality or interpretation of the data obtained from the study.
Exclusion Criteria for Living Donors:
1. There are no exclusion criteria for living donors.
Sites / Locations
- Duke Transplant Center, Duke University Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Cohort 1 (N=5 Subjects)
Cohort 2 (N=10 Subjects)
The two investigational agents used in this study are carfilzomib and belatacept. Per protocol, Carfilzomib administered intravenously: Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43). Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99). Per protocol, Belatacept: -Belatacept will be administered intravenously on days 29 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert.
The enrollment of ten additional subjects and dosing regimen is dependent on the results in Cohort 1.° Per protocol, Carfilzomib administered intravenously: Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43). Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99). Per protocol, Belatacept: -Belatacept will be administered intravenously on days 29 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert. ° May be modified based on the safety and efficacy analysis of Cohort 1.